Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Jaguar Health Inc JAGX

Healthcare
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing... see more

Recent & Breaking News (NDAQ:JAGX)

New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company's Near-Term Commercial & Development Milestones

Accesswire September 4, 2024

Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

Accesswire August 27, 2024

Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award

Accesswire August 20, 2024

Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

Accesswire August 19, 2024

Jaguar Health Reports Second Quarter 2024 Financial Results

Accesswire August 13, 2024

REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial's Clinically Meaningful Results in Breast and Lung Cancer Patients

Accesswire August 12, 2024

Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial's Clinically Meaningful Results

Accesswire August 5, 2024

Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy

Accesswire August 2, 2024

Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting

Accesswire August 1, 2024

Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)

Accesswire July 31, 2024

Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer

Accesswire July 23, 2024

Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning

Accesswire July 18, 2024

Issuance of New European & Australian Patents Bolster IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs)

Accesswire July 8, 2024

Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement

Accesswire June 26, 2024

Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders

Accesswire June 21, 2024

Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024

Accesswire June 12, 2024

Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Accesswire June 7, 2024

Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia

Accesswire May 29, 2024

Investigator-Initiated Trial of Jaguar Health's Crofelemer Yields Positive Results for Functional Diarrhea

Accesswire May 28, 2024

Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product

Accesswire May 23, 2024